SHC
Sotera Health Company
Medical - Diagnostics & Research
Market Cap$4.47B
5Y Perf.-42.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SHC vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-18.4%
SHC vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SHC | DBVT |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology |
| Market Cap | $4.47B | $1712.35T |
| Revenue (TTM) | $1.19B | $0.00 |
| Net Income (TTM) | $118M | $-168M |
| Gross Margin | 55.3% | — |
| Operating Margin | 34.9% | — |
| Forward P/E | 16.3x | — |
| Total Debt | $2.27B | $22M |
| Cash & Equiv. | $346M | $194M |
SHC vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SHC
DBVT
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Sotera Health Compa… (SHC) | 100 | 57.9 | -42.1% |
| DBV Technologies S.… (DBVT) | 100 | 81.6 | -18.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SHC vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SHC leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SHC
Sotera Health Company
The Income Pick
SHC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 1.32
- Rev growth 5.7%, EPS growth 68.8%, 3Y rev CAGR 5.1%
- -37.6% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Defensive Pick
DBVT is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
- Beta 1.26 vs SHC's 1.32, lower leverage
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SHC | 5.7% revenue growth vs DBVT's -100.0% |
| Quality / Margins | SHC | 9.9% margin vs DBVT's 0.3% |
| Stability / Safety | DBVT | Beta 1.26 vs SHC's 1.32, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs SHC's +19.2% |
| Efficiency (ROA) | SHC | 3.7% ROA vs DBVT's -89.0% |
SHC vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
SHC vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSHCLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
SHCSotera Health Company
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SHC1/1
Valuation MetricsMultiples, price ratios, and targets
DBVT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SHC5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
SHC1/1
Income & Cash Flow (Last 12 Months)
SHC leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
SHC and DBVT operate at a comparable scale, with $1.2B and $0 in trailing revenue.
| Metric | SHCSotera Health Com… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $1.2B | $0 |
| EBITDAEarnings before interest/tax | $517M | -$112M |
| Net IncomeAfter-tax profit | $118M | -$168M |
| Free Cash FlowCash after capex | $112M | -$151M |
| Gross MarginGross profit ÷ Revenue | +55.3% | — |
| Operating MarginEBIT ÷ Revenue | +34.9% | — |
| Net MarginNet income ÷ Revenue | +9.9% | — |
| FCF MarginFCF ÷ Revenue | +9.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +2.9% | +91.5% |
SHC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | SHCSotera Health Com… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $4.5B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $6.4B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | 58.04x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.26x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 21.09x | — |
| Price / SalesMarket cap ÷ Revenue | 3.84x | — |
| Price / BookPrice ÷ Book value/share | 7.41x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 29.95x | — |
DBVT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
SHC leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
SHC delivers a 20.6% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to SHC's 3.75x. On the Piotroski fundamental quality scale (0–9), SHC scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | SHCSotera Health Com… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | +20.6% | -130.2% |
| ROA (TTM)Return on assets | +3.7% | -89.0% |
| ROICReturn on invested capital | +11.8% | — |
| ROCEReturn on capital employed | +13.3% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 3.75x | 0.13x |
| Net DebtTotal debt minus cash | $1.9B | -$172M |
| Cash & Equiv.Liquid assets | $346M | $194M |
| Total DebtShort + long-term debt | $2.3B | $22M |
| Interest CoverageEBIT ÷ Interest expense | 2.38x | -189.82x |
SHC leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SHC five years ago would be worth $6,367 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs SHC's +19.2%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs SHC's 1.5% — a key indicator of consistent wealth creation.
| Metric | SHCSotera Health Com… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -11.4% | +4.9% |
| 1-Year ReturnPast 12 months | +19.2% | +110.4% |
| 3-Year ReturnCumulative with dividends | +4.6% | +19.7% |
| 5-Year ReturnCumulative with dividends | -36.3% | -69.1% |
| 10-Year ReturnCumulative with dividends | -37.6% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +1.5% | +6.2% |
DBVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SHC and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than SHC's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | SHCSotera Health Com… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.32x | 1.26x |
| 52-Week HighHighest price in past year | $19.85 | $26.18 |
| 52-Week LowLowest price in past year | $10.80 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +78.9% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 56.5 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 3.1M | 252K |
Evenly matched — SHC and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
SHC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates SHC as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 40.4% for SHC (target: $22).
| Metric | SHCSotera Health Com… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $22.00 | $46.33 |
| # AnalystsCovering analysts | 12 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
SHC leads this category, winning 1 of 1 comparable metric.
Key Takeaway
SHC leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallSotera Health Company (SHC)Leads 3 of 6 categories
Loading custom metrics...
SHC vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SHC or DBVT a better buy right now?
Sotera Health Company (SHC) offers the better valuation at 58.
0x trailing P/E (16. 3x forward), making it the more compelling value choice. Analysts rate Sotera Health Company (SHC) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SHC or DBVT?
Over the past 5 years, Sotera Health Company (SHC) delivered a total return of -36.
3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: SHC returned -37. 6% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SHC or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Sotera Health Company's 1. 32β — meaning SHC is approximately 5% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 4% for Sotera Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — SHC or DBVT?
On earnings-per-share growth, the picture is similar: Sotera Health Company grew EPS 68.
8% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SHC or DBVT?
Sotera Health Company (SHC) is the more profitable company, earning 6.
7% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 6. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHC leads at 33. 8% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — SHC leads at 55. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SHC or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
07Which pays a better dividend — SHC or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SHC or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (DBVT: -87. 0%, SHC: -37. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SHC and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.